| Year |
Citation |
Score |
| 2017 |
Ursu O, Gosline SJC, Beeharry N, Fink L, Bhattacharjee V, Huang SC, Zhou Y, Yen T, Fraenkel E. Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens. Plos One. 12: e0185650. PMID 29023490 DOI: 10.1371/Journal.Pone.0185650 |
0.392 |
|
| 2017 |
Beatty A, Fink LS, Singh T, Strigun A, Peter E, Ferrer CM, Nicolas E, Cai KQ, Moran TP, Reginato MJ, Rennefahrt U, Peterson JR. Metabolite profiling reveals the glutathione biosynthetic pathway as a therapeutic target in triple negative breast cancer. Molecular Cancer Therapeutics. PMID 29021292 DOI: 10.1158/1535-7163.Mct-17-0407 |
0.395 |
|
| 2016 |
Kurimchak AM, Shelton C, Duncan KE, Johnson KJ, Brown J, O'Brien S, Gabbasov R, Fink LS, Li Y, Lounsbury N, Abou-Gharbia M, Childers WE, Connolly DC, Chernoff J, Peterson JR, et al. Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Reports. PMID 27452461 DOI: 10.1016/J.Celrep.2016.06.091 |
0.321 |
|
| 2016 |
Beatty A, Fink L, Strigun A, Rennefahrt U, Peter E, Reszka R, Schiewe H, Peterson JR. Abstract A73: Metabolite profiling reveals the glutathione biosynthetic pathway as a therapeutic target in triple negative breast cancers Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Metca15-A73 |
0.35 |
|
| 2015 |
Fink LS, Beatty A, Devarajan K, Peri S, Peterson JR. Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes. Molecular Cancer Therapeutics. 14: 298-306. PMID 25344583 DOI: 10.1158/1535-7163.Mct-14-0529 |
0.362 |
|
| 2014 |
Beatty A, Fink L, Rennefahrt U, Strigun A, Peter E, Schiewe H, Reszka R, Peterson JR. Abstract 4333: Metabolite profiling reveals druggable metabolic distinctions between basal-like and non-basal-like triple-negative breast cancers Cancer Research. 74: 4333-4333. DOI: 10.1158/1538-7445.Am2014-4333 |
0.35 |
|
| 2013 |
Bitler BG, Fink LS, Wei Z, Peterson JR, Zhang R. A high-content screening assay for small-molecule modulators of oncogene-induced senescence. Journal of Biomolecular Screening. 18: 1054-61. PMID 23733845 DOI: 10.1177/1087057113491827 |
0.339 |
|
| 2013 |
Fink LS, Beatty A, Devarajan K, Peri S, Peterson JR. Abstract 4370: Protein kinase inhibitor screening uncovers differential kinase dependencies in triple negative breast cancer (TNBC). Cancer Research. 73: 4370-4370. DOI: 10.1158/1538-7445.Am2013-4370 |
0.381 |
|
| 2013 |
Beeharry N, Fink L, Banina E, Khazak V, Skobeleva N, Peterson JR, Astsaturov I, Yen TJ. Abstract 3266: Repurposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints. Cancer Research. 73: 3266-3266. DOI: 10.1158/1538-7445.Am2013-3266 |
0.464 |
|
| 2013 |
Beatty A, Fink L, Strigun A, Rennefahrt U, Schmitz O, Schiewe H, Moeller N, Noppinger PR, Reszka R, Peterson JR. Abstract 3222: Broad spectrum metabolite profiling reveals metabolic finger and footprinting which correlate to gene expression signatures of triple-negative breast cancer (TNBC). Cancer Research. 73: 3222-3222. DOI: 10.1158/1538-7445.Am2013-3222 |
0.314 |
|
| 2011 |
Lorenzini A, Fink LS, Stamato T, Torres C, Sell C. Relationship of spindle assembly checkpoint fidelity to species body mass, lifespan, and developmental rate. Aging. 3: 1206-12. PMID 22201071 |
0.453 |
|
| 2011 |
Fink LS, Roell M, Caiazza E, Lerner C, Stamato T, Hrelia S, Lorenzini A, Sell C. 53BP1 contributes to a robust genomic stability in human fibroblasts. Aging. 3: 836-45. PMID 21931182 |
0.573 |
|
| 2010 |
Fink LS, Lerner CA, Torres PF, Sell C. Ku80 facilitates chromatin binding of the telomere binding protein, TRF2. Cell Cycle (Georgetown, Tex.). 9: 3798-806. PMID 20890109 DOI: 10.4161/Cc.9.18.13129 |
0.556 |
|
| Show low-probability matches. |